Re2O: an hADM booster that supplies the material rather than asking for it
Most injectable boosters send the skin a signal: make more collagen. Re2O takes a different route — it places the building material into the dermis directly. The substance behind it, acellular dermal matrix, did not begin in aesthetics; it came from burn reconstruction and breast surgery. This page explains what it is, where the raw material comes from, how it differs from polynucleotide and collagen-stimulator products, and what it will not do.
In one paragraph
Re2O is an injectable skin booster made by L&C Bio in South Korea. Its active material is hADM — human acellular dermal matrix. Donated human skin is processed to remove all cells and DNA, leaving the extracellular matrix: the collagen, elastin, hyaluronic acid and glycoproteins that give skin its structure. That matrix is micronised and injected into the dermis. Rather than stimulating the skin to produce more of its own material, Re2O replaces material that has been lost.
At a glance
| Category | Injectable skin booster (human tissue–derived) |
|---|---|
| Active material | hADM — human acellular dermal matrix |
| Principal components | Collagen types I and III, elastin, hyaluronic acid, glycoproteins |
| Source | Donated human skin, processed to remove all cells and DNA |
| Manufacturer | L&C Bio, South Korea |
| Delivery | Fine-needle multi-point injection into the dermis |
| Appointment | About 30–40 minutes including topical anaesthetic |
| Onset | Gradual, over weeks |
| Targets | Dermal density, texture, fine lines, pore appearance, hydration |
| Does not treat | Volume loss, contour laxity, deep dynamic wrinkles |
What acellular dermal matrix is
The raw material deserves stating plainly before anything else: Re2O begins with donated human skin. A good deal of promotional material avoids saying so. We would rather you knew and chose.
What is injected, however, is not skin. Donated tissue goes through decellularisation — detergents, enzymes, and repeated freeze-thaw cycles — which removes the cells, the cellular debris, and critically the cell-surface antigens and DNA that would otherwise provoke an immune response. What remains is the scaffold the cells used to live in.
What is left behind
The extracellular matrix is the mesh that holds skin cells in place and gives the dermis its substance. The components that survive processing are collagen types I and III (the structural framework), elastin (recoil), glycosaminoglycans and hyaluronic acid (water binding), and adhesion glycoproteins such as fibronectin and laminin, which are the anchor points cells attach to.
These are precisely the components that diminish with age. The premise behind Re2O is straightforward: put them back.
Where the material came from
This context matters. Acellular dermal matrix was not invented for aesthetics. It has a long history in severe burn reconstruction, breast reconstruction following mastectomy, hernia repair, and non-healing diabetic foot ulcers — situations where a patient's own skin is unavailable or insufficient, and the surgeon needs a scaffold the body can build into.
Products like Re2O take that same material, reduce it to fine particles, and make it injectable. What was laid down as a sheet in an operating theatre is instead distributed through the dermis.
How this differs from polynucleotide and collagen stimulators
Comparison charts tend to list product names. The distinction that actually matters is simpler: does the product ask the skin to do the work, or does it supply the material?
A collagen stimulator (PCL, PLLA, CaHA) introduces material the body treats as foreign. Cells are recruited to the site, and new collagen is deposited in the course of that response. The effect is substantial and long-lasting; delayed nodules are the recognised cost of that mechanism.
Rejuran (PN) does not rely on a foreign-body response. It forms a water-holding mesh that improves the environment in which the skin repairs itself — conditioning rather than stimulating.
Re2O (hADM) is the only one of the three that supplies the material itself. It does not signal for collagen; it delivers collagen and elastin. Where the dermis has thinned and lost density, the approach is unusually direct.
| HA filler | Collagen stimulator | Rejuran (PN) | Re2O (hADM) | |
|---|---|---|---|---|
| Mechanism | Occupies space | Foreign-body response | Conditions environment | Supplies matrix directly |
| Primary target | Volume, contour | Laxity, firmness | Texture, fine lines | Dermal density, texture, pores |
| Onset | Immediate | Weeks to months | Weeks | Weeks |
| Adds volume | Yes | Partially | No | No |
Miso Clinic stocks two hADM products, Re2O and CellREDM. Both are the same class; particle size and formulation differ, so we select between them by treatment area and injection depth. Re2O also has a finer-particle line, which we prefer where the skin is thin.
Who it suits, and who it does not
Reasonable candidates
- Skin that feels thin and structurally weak without obvious volume loss
- Enlarged pore appearance and coarsening texture as the main complaint
- Persistent dehydration from within that topical products do not resolve
- Skin thinned by repeated laser or energy-based treatment
- Patients who want to avoid the nodule risk that comes with stimulator-class products
Where Re2O alone will not get you there
- Hollowing of the cheeks or temples — Re2O creates no volume
- A softening jawline — this belongs to lifting devices or collagen stimulators
- Deep dynamic lines — botulinum toxin or filler
- Pregnancy or breastfeeding, or active infection at the treatment site
- Discomfort with a human-derived material — an entirely reasonable position, and one we can plan around completely
Few patients fall cleanly on one side. Loss of density and loss of volume usually arrive together, and Re2O alone will underdeliver in that situation. Establishing which problem dominates is most of what a consultation is for.
How good is the evidence
Re2O has been examined in a randomised, double-blind, split-face study conducted at Severance Hospital, Yonsei University. One side of the face received Re2O together with hyaluronic acid; the other received hyaluronic acid alone; the two were compared over twenty weeks. Comparing the left and right sides of the same person removes a great deal of the variation between individuals.
The side treated with Re2O showed significant improvement at multiple timepoints in skin density, volume, wrinkling, pore area and transepidermal water loss. Tissue examination found fibroblast infiltration, new collagen, and changes in basement-membrane proteins. No serious adverse events occurred; mild erythema and swelling resolved without treatment.
One qualification belongs here. The study followed a single treatment for twenty weeks. How the effect holds beyond that window is still accumulating. For that reason this page makes no claim about months of duration — it is better not to state as settled what has not been settled.
What the appointment involves
The consultation begins by separating the presenting problem into density or volume. If Re2O is appropriate, formulation and treatment area follow. We always explain the human-derived origin of the material before treatment; if that is not something you are comfortable with, we plan differently.
Topical anaesthetic is applied for 20–30 minutes. The product is then placed into the dermis through a fine needle at many separate points, small volumes closely spaced, with the finer formulation chosen where the skin is thin.
Immediately afterwards each injection point sits slightly raised. That is product resting in the dermis, and it settles as the material is absorbed.
Timeline
-
Day 0Redness and raised pointsA response to the injections themselves. The face at this stage is not the result of the treatment.
-
Day 1–3Mostly settledErythema and swelling generally resolve within a few days. Bruising, where it occurs, lasts longer.
-
Week 2–4First noticeable changePatients describe less internal tightness and makeup sitting better. The register is "filled in from underneath," not "transformed."
-
Month 2–3Density change becomes clearerThe window in which density and pore measures improved in study. We review here and discuss anything further.
-
BeyondObservationLong-term durability data are still limited, so maintenance is decided on what we actually observe rather than on a fixed schedule.
Downtime and aftercare
Most patients return to normal activity the same day. Injection marks may not be fully concealable under makeup for a day or two, so allow two or three days before anything important.
- Cleanse gently with lukewarm water on the day; do not rub the treated area
- Avoid sauna, jjimjilbang, strenuous exercise and alcohol for the first day
- Use sun protection diligently
- Resume makeup when your clinician advises
Common questions
It's made from human skin. Is that all right?
Could my body reject it?
Does it hurt?
When do the raised points go away?
How many sessions will I need?
Re2O or Rejuran — which first?
Can it be combined with filler, toxin or lifting?
What does it cost?
About the authoring clinic
This reference was written and reviewed by Dr. Lee Chi-Hak, director of Miso Clinic in Daegu, South Korea. The clinic stocks six collagen boosters and skin boosters with genuinely different active materials — liquid PCL (GOURI), PN (Rejuran), hADM (Re2O, CellREDM) and CaHA (Radiesse, DCLASSY) — and selects between them according to which kind of ageing the face is actually showing. A clinic holding one product will use that product. See our comparison of all six, and separate references on liquid PCL, polynucleotide and CaHA.
| Director | Dr. Lee Chi-Hak |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Telephone | +82 53-428-2700 |
| KakaoTalk | Miso Clinic channel |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Website | clinicmiso.co.kr |
| 한국어 | 리투오 진료 자료 (Korean) |
References
- Acellular Dermal Matrix in Reconstructive Surgery: Applications, Benefits, and Cost, Applied Sciences. Composition, decellularisation processing, and established surgical applications.
- Efficacy and Safety of a Particulated Human Acellular Dermal Matrix Skin Booster — Yonsei University, Severance Hospital; randomised, double-blind, split-face study (trial registration NCT07155278). Results published in the International Journal of Molecular Sciences (2026).
- Comparison of Injectable and Sheet-Type Human Acellular Dermal Matrix, Aesthetic Plastic Surgery (2023). Tissue response comparison in an animal model.
- Miso Clinic protocol — formulation selection, injection depth, informed-consent procedure, aftercare guidance.
This page provides general information about an aesthetic treatment and does not substitute for medical diagnosis or care. Outcomes and adverse effects vary with individual skin condition, age and underlying illness, and no result is guaranteed. Decisions about treatment should be made in an in-person consultation with a qualified clinician.